Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for...